Stockreport

BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment [Yahoo! Finance]

Protagonist Therapeutics, Inc.  (PTGX) 
Last protagonist therapeutics, inc. earnings: 3/10 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.protagonist-inc.com
PDF In the polycythemia vera space, BESREMi faces competition from drugs like ruxolitinib, a JAK1/2 inhibitor, and hydroxyurea. However, BESREMi differentiates itself by bei [Read more]